Fmr LLC Replimune Group, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Fmr LLC holds 747,188 shares of REPL stock, worth $9.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

747,188

Previous 286,479 160.82%

Holding current value

$9.34 Million

Previous $2.34 Million 187.35%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$5.01 - $9.46 $2.31 Million - $4.36 Million	460,709 Added 160.82%	747,188 $6.72 Million
Q1 2024 May 13, 2024	SELL	$6.87 - $9.31 $3.71 Million - $5.02 Million	-539,382 Reduced 65.31%	286,479 $2.34 Million
Q4 2023 Feb 13, 2024	SELL	$6.75 - $16.18 $2.99 Million - $7.16 Million	-442,822 Reduced 34.9%	825,861 $6.96 Million
Q3 2023 Nov 13, 2023	SELL	$15.96 - $22.18 $4.4 Million - $6.12 Million	-275,885 Reduced 17.86%	1,268,683 $21.7 Million
Q2 2023 Aug 11, 2023	BUY	$15.65 - $24.1 $6.12 Million - $9.43 Million	391,114 Added 33.91%	1,544,568 $35.9 Million
Q1 2023 May 11, 2023	SELL	$17.48 - $29.09 $3.97 Million - $6.6 Million	-226,980 Reduced 16.44%	1,153,454 $20.4 Million
Q4 2022 Feb 13, 2023	BUY	$17.09 - $27.91 $4.92 Million - $8.03 Million	287,681 Added 26.33%	1,380,434 $37.5 Million
Q3 2022 Nov 10, 2022	BUY	$15.6 - $21.15 $39,670 - $53,784	2,543 Added 0.23%	1,092,753 $18.9 Million
Q2 2022 Aug 12, 2022	BUY	$13.32 - $19.98 $124,941 - $187,412	9,380 Added 0.87%	1,090,210 $19.1 Million
Q1 2022 May 13, 2022	BUY	$15.24 - $29.75 $407,075 - $794,652	26,711 Added 2.53%	1,080,830 $18.4 Million
Q2 2021 Aug 13, 2021	BUY	$28.5 - $39.37 $30 Million - $41.5 Million	1,054,119 New	1,054,119 $40.5 Million

Others Institutions Holding REPL

# of Institutions

158

Shares Held

70M

Call Options Held

26.7K

Put Options Held

28.6K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $616M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account